Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Dermatology

Living with LAD: Prognosis, Follow-up, and Daily Management

At a Glance

Living with linear IgA dermatosis involves regular follow-up, especially when taking dapsone, plus prompt attention to eye or airway symptoms and gentle skin care. Children often achieve remission, while adults may have relapses or need long-term treatment.

The course of Linear IgA Dermatosis (LAD) or Chronic Bullous Disease of Childhood (CBDC) is variable, and living with it means focusing on consistent management. While some cases resolve, others can become a chronic condition, and your relationship with your medical team—which may eventually include dermatologists, eye doctors, and specialists in ear, nose, and throat (ENT) care—is the key to a good long-term outcome [1][2].

Long-Term Outlook (Prognosis)

The course of LAD varies significantly depending on age and the areas of the body involved.

  • Children (CBDC): The outlook is generally positive. In small studies, the average duration of the disease is about 38 months (just over 3 years) [3]. While the initial phase can be severe and may even require hospitalization, many children eventually enter complete remission, meaning the disease resolves entirely [3][4].
  • Adults (Idiopathic): The path for adults is often more complex. In one group of patients followed for over three years, 36% achieved lasting remission, while 29% experienced relapses (periods where the blisters returned) [1]. Roughly 35% of adults developed a chronic form of the disease that required ongoing medication [1].
  • Predicting Remission: You are more likely to have a shorter, smoother course if you are over the age of 70 at diagnosis or if the disease does not involve your mucosa (the mouth, eyes, or other moist linings) [1].

Safe Monitoring on Dapsone

If you are prescribed dapsone, the “gold standard” treatment, you will need frequent blood tests, especially in the first few months. This monitoring is not optional; it is required to catch side effects before they become serious [5][6].

  • Blood Counts (CBC) and Reticulocytes: These tests check for hemolysis (the breakdown of red blood cells) and agranulocytosis (a dangerous drop in white blood cells) [5][6].
  • Liver and Kidney Function: Dapsone can occasionally cause drug-induced liver injury or changes in kidney function, so your doctor will establish a clinician-directed baseline and follow-up plan based on your dose and local protocol [7][8].
  • Oxygen Checks: Your doctor may monitor your methemoglobin levels. If these levels get too high, your blood cannot carry oxygen effectively, leading to fatigue, headaches, or a bluish tint to the skin (cyanosis) [9][10].

Multidisciplinary Care and Safety

Because LAD can affect parts of the body you cannot easily see, you may need a “team” approach to care.

  • Ophthalmology (Eye Care): Any eye symptoms—redness, pain, or light sensitivity—require an urgent evaluation by an eye specialist [2][11]. Scarring in the eyes can be progressive and may continue even after the skin blisters have healed, making long-term eye follow-up essential [12][13].
  • ENT and Anesthesia Safety: If the disease involves your throat or airway, it makes the lining very fragile [14][2]. Crucial Warning: If you ever need surgery or a procedure requiring a breathing tube (intubation), you must inform the anesthesia team about your LAD. Standard intubation can cause significant airway bleeding in LAD patients whose airway or upper respiratory mucosa is known or suspected to be involved; your doctors must plan for a “gentle” airway management strategy [2].

Daily Management and Wound Care

Caring for your skin daily can help prevent infections and reduce discomfort.

  • Gentle Handling: Blisters in LAD can sometimes form in response to skin trauma or friction (the Koebner phenomenon) [15]. Wear loose-fitting clothing and handle your skin gently to avoid triggering new lesions [15].
  • Wound Care: For open sores or erosions, your doctor may recommend non-adherent (non-stick) dressings or wet occlusive wraps to help the skin re-epithelialize (heal over) [16][17].
  • Itch Management: The “pruritus” (itching) in LAD can be intense. While dapsone helps, some patients may need additional medications to control the itch and improve their quality of life [18][19].

Common questions in this guide

What is the long-term outlook for a child with linear IgA dermatosis?
Many children eventually enter complete remission, meaning the disease resolves, although the initial phase can be severe and may require hospital care. Small studies report an average course of about three years, but each child’s timeline is different.
Can LAD come back or become chronic in adults?
Yes. Adult LAD may go into lasting remission, relapse with new blisters, or continue as a chronic condition that needs ongoing medication. The outlook is influenced in part by age at diagnosis and whether the mouth, eyes, or other moist linings are involved.
Which tests are needed while taking dapsone for LAD?
Your clinician may order a complete blood count and a reticulocyte count, a test related to new red blood cells, to look for red-cell breakdown or a dangerous drop in white blood cells. Liver and kidney tests, and sometimes a methemoglobin test that checks how well blood carries oxygen, may also be needed, especially during the first few months.
Which eye symptoms require urgent attention with LAD?
Eye redness, pain, or sensitivity to light should be evaluated promptly by an ophthalmologist. Eye scarring can continue even after skin blisters improve, so people with eye or other mucosal involvement may need long-term eye follow-up.
Why should I tell the anesthesia team about LAD before a procedure?
If LAD affects or may affect the throat or airway, the lining can be fragile and standard placement of a breathing tube can cause bleeding. Tell the anesthesia team before surgery or endoscopy so they can plan a gentler approach to managing the airway.
How can I protect LAD blisters and open sores at home?
Loose-fitting clothing and gentle handling can reduce friction and trauma that trigger new blisters. A clinician may recommend non-stick dressings or wet wraps for open sores, and increasing redness, pus, or worsening pain should be reported because these may signal infection.
When can dapsone be reduced if I have no new blisters?
Dapsone should not be tapered or stopped without the prescriber’s direction. If you remain blister-free, your dermatologist can decide whether a gradual reduction is appropriate by reviewing your symptoms, mucosal involvement, and blood-test results.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Linear IgA dermatosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the specific schedule for my (or my child's) blood tests (CBC, reticulocytes, and liver enzymes) during the first three months of dapsone?
  2. 2.Since I have mucosal involvement, can you recommend an ophthalmologist who has experience with autoimmune blistering diseases?
  3. 3.If I or my child needs surgery or an endoscopy, how will you communicate our airway risks to the anesthesia team?
  4. 4.What signs of secondary infection (like pus or increasing redness) should I look for in my blisters?
  5. 5.At what point will we consider tapering my medication if I remain blister-free?

References

References (19)
  1. 1

    Idiopathic linear IgA bullous dermatosis: prognostic factors based on a case series of 72 adults.

    Gottlieb J, Ingen-Housz-Oro S, Alexandre M, et al.

    The British journal of dermatology 2017; (177(1)):212-222 doi:10.1111/bjd.15244.

    PMID: 27995619
  2. 2

    Airway management of a patient with linear immunoglobulin A bullous dermatosis: A case report.

    Nin OC, Hutnik R, Chheda NN, Hutchinson D

    World journal of clinical cases 2024; (12(13)):2263-2268 doi:10.12998/wjcc.v12.i13.2263.

    PMID: 38808340
  3. 3

    Linear IgA bullous dermatosis of childhood: Retrospective single-center cohort.

    Wang KL, Lehman JS, Davis DMR

    Pediatric dermatology 2024; (41(3)):461-464 doi:10.1111/pde.15567.

    PMID: 38378007
  4. 4

    Linear IgA bullous dermatosis in adults and children: a clinical and immunopathological study of 38 patients.

    Genovese G, Venegoni L, Fanoni D, et al.

    Orphanet journal of rare diseases 2019; (14(1)):115 doi:10.1186/s13023-019-1089-2.

    PMID: 31126328
  5. 5

    Development of a multivariate predictive model for dapsone adverse drug events in people with leprosy under standard WHO multidrug therapy.

    de Araujo ACGDS, Hacker MAV, Pinheiro RO, et al.

    PLoS neglected tropical diseases 2024; (18(1)):e0011901 doi:10.1371/journal.pntd.0011901.

    PMID: 38271456
  6. 6

    Diaminodiphenyl Sulfone-Induced Hemolytic Anemia and Alopecia in a Case of Linear IgA Bullous Dermatosis.

    Akasaka E, Kayo SJ, Nakano H, et al.

    Case reports in dermatology 2015; (7(2)):183-6 doi:10.1159/000438506.

    PMID: 26351428
  7. 7

    Dapsone-induced hepatic complications: it's time to think beyond methemoglobinemia.

    Ezhilarasan D

    Drug and chemical toxicology 2021; (44(3)):330-333 doi:10.1080/01480545.2019.1679829.

    PMID: 31631707
  8. 8

    Dapsone in the treatment of pemphigus vulgaris: adverse effects and its importance as a corticosteroid sparing agent.

    Quaresma MV, Bernardes Filho F, Hezel J, et al.

    Anais brasileiros de dermatologia 2015; (90(3 Suppl 1)):51-4.

    PMID: 26312673
  9. 9

    A Case of Dapsone-induced Mild Methemoglobinemia with Dyspnea and Cyanosis.

    Hayama Y, Imanishi H, Yoshimoto N, et al.

    Acta dermatovenerologica Croatica : ADC 2020; (28(4)):249-250.

    PMID: 33835002
  10. 10

    Linear IgA bullous dermatosis associated with ulcerative proctitis: treatment challenge.

    Yetto T, Burns C

    Dermatology online journal 2018; (24(7)).

    PMID: 30261573
  11. 11

    A Case of Linear IgA Bullous Dermatosis of Childhood With Ocular Involvement: A Diagnostic Challenge.

    Haidar H, Amos-Oluwole O, Loomba A, et al.

    Cornea 2026; (45(8)):1051-1055 doi:10.1097/ICO.0000000000004087.

    PMID: 42241023
  12. 12

    Localized Linear IgA Bullous Dermatosis and a Recurrent Cicatricial Ectropion of the Eyelid: A Case Report of a Sixteen-Year Follow-up.

    Drnovšek-Olup B, Matović K

    Indian journal of dermatology 2022; (67(6)):835 doi:10.4103/ijd.ijd_909_20.

    PMID: 36998840
  13. 13

    Combined Use of Rituximab and Intravenous Immunoglobulin for Severe Autoimmune Cicatricial Conjunctivitis-An Interventional Case Series.

    Steger B, Madhusudan S, Kaye SB, et al.

    Cornea 2016; (35(12)):1611-1614 doi:10.1097/ICO.0000000000001024.

    PMID: 27661067
  14. 14

    Clinical features of chronic bullous dermatosis of childhood.

    Wilson A, Murrell DF

    Clinical and experimental dermatology 2022; (47(5)):873-881 doi:10.1111/ced.15059.

    PMID: 34919291
  15. 15

    An array of unusual clinical features in a woman with amlodipine-induced linear immunoglobulin A disease.

    Ailawadi P, Narang I, Garg VK

    International journal of women's dermatology 2019; (5(2)):92-95 doi:10.1016/j.ijwd.2018.11.004.

    PMID: 30997380
  16. 16

    Drug-Induced Linear IgA Bullous Dermatosis Emerging After Vancomycin Discontinuation in Renal Impairment: Management Amid Serious Infection.

    Peake KE, Chow EY

    Cureus 2025; (17(8)):e91255 doi:10.7759/cureus.91255.

    PMID: 41030698
  17. 17

    Management of Recurrent Linear IgA Dermatosis of Childhood in the Absence of Histopathology and Immunofluorescence: A Case Report from a Low-Resource Setting in South-Western Uganda.

    Olwit G, Nek AJ, Chris-Uchendu HC, et al.

    Clinical, cosmetic and investigational dermatology 2026; (19()):619152 doi:10.2147/CCID.S619152.

    PMID: 42299444
  18. 18

    [Linear IgA bullous dermatosis].

    Juratli HA, Sárdy M

    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 2019; (70(4)):254-259 doi:10.1007/s00105-019-4377-9.

    PMID: 30874843
  19. 19

    Case report: Dupilumab: a promising treatment option for adult linear IgA bullous dermatosis with severe pruritus.

    Wang L, Peng J, Chen J

    Frontiers in immunology 2024; (15()):1409556 doi:10.3389/fimmu.2024.1409556.

    PMID: 39161758

This page is for informational purposes only and does not constitute medical advice about linear IgA dermatosis or dapsone monitoring. Your dermatologist and other specialists should tailor follow-up, wound care, and procedure safety to your situation.